Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. ====== Edelfosine ====== {{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/1LU7YBGfC-yPn9_8X6AgyfBgN6_0ItMpmj5HjaASvv51av_cka/?limit=15&utm_campaign=pubmed-2&fc=20240125062838}} ---- ---- The ether lipid edelfosine is the prototype of a family of synthetic antitumor compounds collectively known as [[alkylphospholipid analog]]s, and its antitumor activity involves [[lipid raft reorganization]]. Alonso-Pérez et al. examined the effect of edelfosine on metastatic [[colonization]] and [[angiogenesis]]. Using non-invasive [[bioluminescence]] imaging and histological examination, they found that oral administration of edelfosine in [[nude mice]] significantly inhibited the lung and brain colonization of luciferase-expressing 435-Lung-eGFP-CMV/Luc metastatic cells, resulting in prolonged survival. In metastatic 435-Lung and [[MDA-MB-231]] breast cancer cells, they found that edelfosine also inhibited [[cell adhesion]] to collagen-I and laminin-I substrates, [[cell migration]] in [[chemotaxis]] and wound-healing assays, as well as cancer [[cell invasion]]. In 435-Lung and other MDA-MB-435-derived sublines with different organotropism, edelfosine induced G2/M [[cell cycle]] accumulation and apoptosis in a concentration- and time-dependent manner. Edelfosine also inhibited in vitro angiogenesis in human and mouse endothelial cell tube formation assays. The antimetastatic properties were specific to cancer cells, as edelfosine had no effects on viability in non-cancerous cells. Edelfosine accumulated in membrane rafts and [[endoplasmic reticulum]] of cancer cells, and membrane raft-located [[CD44]] was downregulated upon drug treatment. Taken together, this study highlights the potential of edelfosine as an attractive drug to prevent metastatic growth and organ colonization in cancer therapy. The raft-targeted drug edelfosine displays a potent activity against metastatic organ [[colonization]] and [[angiogenesis]], two major hallmarks of tumor [[malignancy]] ((Alonso-Pérez V, Hernández V, Calzado MA, Vicente-Blázquez A, Gajate C, Soler-Torronteras R, DeCicco-Skinner K, Sierra A, Mollinedo F. Suppression of metastatic organ colonization and [[antiangiogenic]] activity of the orally bioavailable lipid raft-targeted alkylphospholipid edelfosine. Biomed Pharmacother. 2024 Jan 23;171:116149. doi: 10.1016/j.biopha.2024.116149. Epub ahead of print. PMID: 38266621.)) edelfosine.txt Last modified: 2024/06/07 02:55by 127.0.0.1